Document Detail


Enhancing myocardial plasmid expression by retrograde coronary venous delivery.
MedLine Citation:
PMID:  16003788     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Myocardial delivery of genes holds great promise for treating many heart diseases; however, the optimal delivery technique, which maximizes safety and efficacy, has not been established. Two delivery techniques were evaluated in swine; percutaneous retrograde coronary venous delivery (RCVD) and direct intramyocardial injection (IM). RCVD was performed in the anterior interventricular vein (AIV) with an end-hole occlusion balloon catheter. The plasmid gWiz, encoding beta-galactosidase (10 ml; 1 mg/ml), was injected using either manual high pressure (HP-RCVD; n = 5) or pressure wire-guided low pressure (LP-RCVD; n = 4). For the IM group (n = 4), beta-Gal plasmid (5 mg/ml) was injected at 10 sites (200 microl/site) in the anterior left ventricular wall. Animals were euthanized after 5 days. The percentage of beta-Gal expressing cells in the delivered region was higher in the HP-RCVD (0.26% +/- 0.05%) than the LP-RCVD (0.05% +/- 0.03%; P = 0.07) and IM groups (0.02% +/- 0.01%; P = 0.01). Myocardium from the HP-RCVD group contained 7- and 17-fold higher levels of beta-Gal activity than either LP-RCVD and IM groups, respectively (P = 0.05 for both). The results of this study confirm the safety and efficacy of RCVD for myocardial gene delivery.
Authors:
Eyas Al-Shaykh Youssef; Ping Zhang; Pamela I Rogers; Patrice Tremble; Joe Rokovich; Brian H Johnstone; Keith L March; Dongming Hou
Related Documents :
843418 - Comparison of the effects of labetalol and propranolol in healthy men at rest and durin...
14553968 - Beta-blockers in hypertension-the emperor has no clothes: an open letter to present and...
94618 - Acute and chronic beta-receptor blockage with propranolol and the cardiovascular respon...
25262278 - Role of pleth variability index for predicting hypotension after spinal anesthesia for ...
22329678 - Application of atmospheric pressure non-thermal plasma for the in vitro eradication of ...
3836858 - Changes in blood pressure and thermographic values resulting from use of a beta-blocker...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  65     ISSN:  1522-1946     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-07-27     Completed Date:  2005-12-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  528-34     Citation Subset:  IM    
Affiliation:
Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Pressure / physiology
Coronary Circulation / physiology*
Coronary Vessels / metabolism*,  physiopathology*
Disease Models, Animal
Female
Heart Ventricles / metabolism
Humans
Male
Models, Cardiovascular
Myocardial Ischemia / metabolism,  physiopathology
Myocardium / metabolism*,  pathology
Plasmids / administration & dosage,  biosynthesis*
Swine
beta-Galactosidase / metabolism
Chemical
Reg. No./Substance:
EC 3.2.1.23/beta-Galactosidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Drug-eluting stents for coronary bifurcations: bench testing of provisional side-branch strategies.
Next Document:  Metathesis reactions in total synthesis.